Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2191-2199

  Sarveswaran, Sivalokanathan ^a   Gautam, Subhash C ^a   Ghosh, Jagadananda ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

5 Lipoxygenase; Apoptosis; Prostate cancer; Protein kinase C ; Wedelolactone

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CASPASE 3; LIPOCORTIN 5; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; STRESS ACTIVATED PROTEIN KINASE; WEDELOLACTONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; MALE; MAP KINASE KINASE 4; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84869783143     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1664     Document Type: Article

References (54)

1. Govindachari T, Nagarajan K and Pai B: Wedelolactone from Eclipta alba. J Sci Indust Res 15B: 664-665, 1956.
2. Wagner H, Geyer B, Kiso Y, Hikino H and Rao GS: Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Med 52: 370-374, 1986. (Pubitemid 17195170)
3. Singh B, Saxena AK, Chandan BK, Agarwal SG and Anand KK: In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian J Physiol Pharmacol 45: 435-441, 2001. (Pubitemid 33026896)
4. Patel MB, Kadakia VM and Mishra SH: Simultaneous estimation of andrographolide and wedelolactone in herbal formulations. Indian J Pharma Sci 70: 689-693, 2008.
5. Roy RK, Thakur M and Dixit VK: Hair growth promoting activity of Eclipta alba in male albino rats. Arch Dermatol Res 300: 357-364, 2008.
6. Mors WB, do Nascimento MC, Parente JP, da Silva MH, Melo PA and Suarez-Kurtz G: Neutralization of lethal and myotoxic activities of South American rattlesnake venom by extracts and constituents of the plant Eclipta prostrata (asteraceae). Toxicon 27: 1003-1009, 1989. (Pubitemid 19226954)
7. Melo PA, Nascimento MC, Mors WB and Suarez-Kurtz G: Inhibition of the myotoxic and hemorrhagic activities of crotalid venoms by Eclipta prostrata (asteraceae) extracts and constituents. Toxicon 32: 595-603, 1994. (Pubitemid 24162717)
8. Melo PA and Ownby CL: Ability of wedelolactone, heparin, and para-bromophenacyl bromide to antagonize the myotoxic effects of two crotaline venoms and their PLA2 myotoxins. Toxicon 37: 199-215, 1999. (Pubitemid 28513000)
9. Soares AM, Januario AH, Lourenco MV, Pereira AM and Pereira PS: Neutralizing effects of Brazilian plants against snake venoms. Drugs Fut 29: 1105-1109, 2004.
10. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, Angelica M, Gakidis M, Rao A, Sekine T, Ikegami F, Yuan C and Yuan J: Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 11: 123-130, 2004. (Pubitemid 38111379)
11. Syed SD, Deepak M, Yogisha S, Chandrashekar AP, Muddarachappa KA, D'Souza P, Agarwal A and Venkataraman BV: Trypsin inhibitory effect of wedelolactone and demethylwedelolactone. Phytother Res 17: 420-421, 2003. (Pubitemid 36565356)
12. Sagar BP, Panwar R, Goswami A, Kadian K, Tyagi K, Chugh M, Dalal S and Zafar R: Pharmacokinetic interactions of antihepatotoxic wedelolactone with paracetamol in wistar albino rats. Pharmaceutical Biol 44: 554-561, 2006. (Pubitemid 44582024)
13. Diogo LC, Fernandes RS, Marcussi S, Menaldo DL, Roberto PG, Matrangulo PV, Pereira PS, Franca SC, Giuliatti S, Soares AM and Lourenco MV: Inhibition of snake venoms and phospholipases A2 by extracts from native and genetically modified Eclipta alba: isolation of active coumestans. Basic Clin Pharmacol Toxicol 104: 293-299, 2009.
14. Pithayanukul P, Lapett B, Bavovada R, Pakmanee N and Suttisri R: Inhibition of proteolytic and hemorrhagic activities by ethyl acetate extract of Eclipta prostrata against Malayan pit viper venom. Pharmaceutical Biol 45: 282-288, 2007. (Pubitemid 47024403)
15. Lin FM, Chen LR, Lin EH, Ke FC, Chen HY, Tsai MJ and Hsiao PW: Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 28: 2521-2529, 2007.
16. Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PR, da Silva AJ, Sarafianos SG and Noel F: Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 36: 1482-1496, 2008. (Pubitemid 351426102)
17. Wagner H and Fessler B: In vitro 5-lipoxygenase inhibition by Eclipta alba extracts and the coumestan derivative wedelolactone. Planta Med 52: 374-377, 1986 (In German). (Pubitemid 17195171)
18. Werz O: Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta Med 73: 1331-1357, 2007.
19. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG and Mukhtar H: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91: 737-743, 2001. (Pubitemid 32173298)
20. Ghosh J and Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95: 13182-13187, 1998. (Pubitemid 28509545)
21. Ghosh J and Myers CE: Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol 469: 577-582, 1999.
22. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, Ou D and Harris JH: 5-lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37: 161-173, 1998. (Pubitemid 28487899)
23. Moretti RM, Montagnani MM, Sala A, Motta M and Limonta P: Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer 112: 87-93, 2004. (Pubitemid 39249495)
24. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D and Newman RA: Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 55: 281-291, 2003. (Pubitemid 36618186)
25. Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 24: 821-827, 2004.
26. Ghosh J: Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 307: 342-349, 2003.
27. Cregan SP, Dawson VL and Slack RS: Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 23: 2785-2796, 2004. (Pubitemid 38638842)
28. Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene 27: 6245-6251, 2008.
29. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, and Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994. (Pubitemid 24153440)
30. Kyriakis JM, and Avruch J: Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316, 1996. (Pubitemid 26333156)
31. Maroney AC, Finn JP, Bozyczko-Coyne D, O'Kane TM, Neff NT, Tolkovsky AM, Park DS, Yan CY, Troy CM and Greene LA: CEP-1347 (KT 7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem 73: 1901-1912, 1999. (Pubitemid 29491803)
32. Sarveswaran S, Myers CE and Ghosh J: MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett 291: 167-176, 2010.
33. Sarveswaran S, Thamilselvan V, Brodie C and Ghosh J: Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epslilon. Biochim Biophys Acta 1813: 2108-2117, 2011.
34. Benes P, Knopfova L, Trcka F, Nemajerova A, Pinheiro D, Soucek K, Fojta M and Smarda J: Inhibition of topoisomerase IIα: novel function of wedelolactone. Cancer Lett 303: 29-38, 2011.
35. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983. (Pubitemid 13122588)
36. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979. (Pubitemid 9239413)
37. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281, 1978. (Pubitemid 8283045)
38. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225, 2003. (Pubitemid 37267805)
39. Logue SE, Elgendy M and Martin SJ: Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc 4: 1383-1395, 2009.
40. Duriez PJ and Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349, 1997. (Pubitemid 127733184)
41. Hurd PJ, Bannister AJ, Halls K, Dawson MA, Vermeulen M, Olsen JV, Ismail H, Somers J, Mann M, Owen-Hughes T, Gout I and Kouzarides T: Phosphorylation of histone H3 Thr-45 is linked to apoptosis. J Biol Chem 284: 16575-16583, 2009.
42. Radic M, Marion T and Monestier M: Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 172: 6692-6700, 2004. (Pubitemid 38669105)
43. Ziegler DS and Kung AL: Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 20: 97-103, 2008. (Pubitemid 350190988)
44. Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002. (Pubitemid 37328781)
45. Mashima T and Tsuruo T: Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat 8: 339-343, 2005. (Pubitemid 43358057)
46. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M and Izumo S: Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 277: 10244-10250, 2002. (Pubitemid 34968139)
47. Horbinski C and Chu CT: Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic Biol Med 38: 2-11, 2005. (Pubitemid 39626903)
48. Logue SE and Martin SJ: Caspase activation cascades in apoptosis. Biochem Soc Trans 36: 1-9, 2008. (Pubitemid 351269611)
49. Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998. (Pubitemid 28183012)
50. Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C and Martin SJ: Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci USA 105: 12815-12819, 2008.
51. Keith S, Abayasiriwardana D, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, Hunt AE, Evan GI and Broaddus VC: Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 6: 2766-2776, 2007. (Pubitemid 350058156)
52. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
53. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K and Klocker H: Switch from antagonist to agonist of the androgen receptor: bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81: 242-251, 1999. (Pubitemid 29423702)
54. Namiki M, Ueno S, Kitagawa Y, Konaka H, Mizokami A, Koh E and Fukagai TY: Hormonal therapy. Int J Clin Oncol 12: 427-432, 2007. (Pubitemid 350243837)